• 1
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer JClin. 2007; 57: 43-66.
  • 2
    Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Trans. 2005; 33: 241-245.
  • 3
    Konig J, Hartel M, Nies AT, Martignoni ME, Guo J, Buchler MW et al. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer. 2005; 115: 359-367.
  • 4
    Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006; 112: 457-473.
  • 5
    Letourneau IJ, Deeley RG, Cole SP. Functional characterization of non- synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics. 2005; 15: 647-657.
  • 6
    Zhao YP, Zhang LY, Liao Q, Guo JC, Chen G, Li JY. Detection of multidrug resistant gene 1 in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2004; 3: 307-310.
  • 7
    O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, et al. MDR1/P-glycoprotein and MRP1 drug efflux pumps in pancreatic carcinoma. Anticancer Res. 2007; 27: 2115-2120.
  • 8
    Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003; 88: 1963-1970.
  • 9
    Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer. 1997; 75: 869-877.
  • 10
    Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1(MDR1), ABCC (MRP), ABCG (BCRP) efflux transporters. Int J Toxicol. 2006; 25: 231-259.
  • 11
    Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004; 15: 1194-1203.
  • 12
    Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics. 2004; 14: 155-164.
  • 13
    Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006; 45: 253-285.
  • 14
    Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drug: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics. 2005; 6: 115-138.
  • 15
    Obata H, Yahata T, Quan J, Sekine M, Tanaka K. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res. 2006; 26: 2227-2232.
  • 16
    Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487-3495.
  • 17
    Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3502.
  • 18
    Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127: 1335-1339.
  • 19
    Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96: 434-442.
  • 20
    Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, et al. Characterization of the transport of nucleoside analog drugs by human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003; 63: 1094-1103.
  • 21
    Davidson JD, Ma L, Iverson PW, Lesoon A, Jin S, Horwitz L, et al. Human multi-drug resistance protein 5 (MRP5) confers resistance to gemcitabine. Proc Am Assoc Cancer Res. 2002; 43: 3868.
  • 22
    Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M, et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther. 2006; 5: 1800-1806.
  • 23
    Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, et al. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J Hum Genet. 2002; 47: 147-171.
  • 24
    Adachi M, Reid G, Schuetz JD. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev. 2002; 18: 1333-1342.
  • 25
    Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007; 315: 525-528.
  • 26
    Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 1999; 59: 5964-5967.
  • 27
    Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001; 276: 46400-46407.
  • 28
    Borst P, Zelcer N, van de Wetering K. MRP2 and 3 in health and disease. Cancer Lett. 2006; 234: 51-61.
  • 29
    Mizuarai, S., Aozasa, N., & Kotani, H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer. 2004; 109: 238-246.
  • 30
    Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006; 24: 1720-1728.
  • 31
    Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res. 2008; 14: 2042-2048.
  • 32
    Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, et al. Significant association of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009; 27: 1592-1599.
  • 33
    Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res. 2010; 16: 320-329.